Key result
Long-term treatment with amlodipine and olmesartan medoxomil, with or without hydrochlorothiazide, reduced seated blood pressure by a mean of 32.4/19.6 mm Hg and achieved blood pressure goals in 66.7% of patients.
Why the study?
Does amlodipine + olmesartan medoxomil ± hydrochlorothiazide improve blood pressure control in hypertensive patients across different age, race, and diabetes subgroups?
Does amlodipine + olmesartan medoxomil ± hydrochlorothiazide improve blood pressure control in hypertensive patients across different age, race, and diabetes subgroups?
Amlodipine plus olmesartan with or without hydrochlorothiazide effectively lowers blood pressure across age and race subgroups, though goal achievement is notably lower in patients with diabetes.
Answers are grounded in this paper and cite their sources.
Supports long-term amlodipine-olmesartan use for hypertension; extends short-term RCT data to sustained BP control.
A prespecified subgroup analysis of a 44-week open-label extension study is presented. The efficacy and safety of the combination of amlodipine (AML) + olmesartan medoxomil (OM), with and without the addition of hydrochlorothiazide (HCTZ), were investigated in patients aged ≥65 and <65 years, Blacks and non-Blacks and patients with and without type 2 diabetes. After an 8-week double-blind, placebo-controlled portion of the study, patients initiated therapy on AML 5 + OM 40 mg per day, were uptitrated stepwise to AML 10 + OM 40 mg per day, with the addition of HCTZ 12.5 mg, and 25 mg if blood pressure (BP) goal was not achieved (<140/90 or <130/80 mm Hg for patients with diabetes). Endpoints included the change from baseline in mean seated systolic BP, mean seated diastolic BP and achievement of BP goal. BP decreased from baseline for all treatments in each prespecified subgroup. By the end of the study, BP goal was achieved in 61.0% of patients aged ≥65 years, 68.1% of patients aged <65 years, 63.3% of Blacks, 67.8% of non-Blacks, 26.9% of patients with diabetes and 72.9% of patients without diabetes. The combination of AML + OM ± HCTZ was efficacious, safe and well tolerated by these subgroups.
No takes yet. Share an insight, caveat, or question.
Oparil et al. (2010) studied Hypertension (n=1,684). Amlodipine + olmesartan medoxomil ± hydrochlorothiazide was evaluated on Achievement of blood pressure goal (<140/90 mm Hg or <130/80 mm Hg for patients with diabetes) at Week 52/early termination. Long-term treatment with amlodipine and olmesartan medoxomil, with or without hydrochlorothiazide, reduced seated blood pressure by a mean of 32.4/19.6 mm Hg and achieved blood pressure goals in 66.7% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: